MedTrace Logo

The Use of L-arginine to Mitigate the Cardiovascular Effects of Exposure to Traffic-related Air Pollution

NCT03433963 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2021-03-10

No results posted yet for this study

Summary

The present study is aimed to investigate whether oral L-arginine supplementation reduces the adverse cardiovascular effects of exposure to traffic-related air pollution among a group of non-smoking adults with elevated blood pressure.

Conditions

  • Blood Pressure
  • Cardiac Ischemia

Interventions

DIETARY_SUPPLEMENT

L-Arg supplement

L-Arg supplement will be prepared as pills, administered 9g each day in 3 times for 2 weeks.

DIETARY_SUPPLEMENT

Placebo

Placebo will be prepared as pills (the same size, color and shape as of L-Arg), administered 3 times daily for 2 weeks.

Sponsors & Collaborators

  • Peking University

    lead OTHER

Principal Investigators

  • Shaowei Wu, PhD · Peking University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-02
Primary Completion
2019-07-04
Completion
2020-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03433963 on ClinicalTrials.gov